PureTech Health (GB:PRTC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PureTech Health is poised to present pivotal data on LYT-100, a promising treatment for idiopathic pulmonary fibrosis (IPF), at CHEST 2024 Annual Meeting in Boston. The company expects to unveil topline results from the Phase 2b ELEVATE IPF trial by year-end and aims to progress to a Phase 3 trial, potentially setting the stage for a new standard in IPF care. With LYT-100 designed to offer improved tolerability over existing treatments, PureTech is targeting a larger market of patients currently underserved due to side effects of current IPF medications.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.